BR9600079A - Composto e intermediário para sua preparação composicão farmacêutica método para tratar ou prevenir osteosporose doenças cardiovasculares doença prostática obesidade câncer de mama endometriose e para baixar os niveis de colesterol no soro saguíneo - Google Patents
Composto e intermediário para sua preparação composicão farmacêutica método para tratar ou prevenir osteosporose doenças cardiovasculares doença prostática obesidade câncer de mama endometriose e para baixar os niveis de colesterol no soro saguíneoInfo
- Publication number
- BR9600079A BR9600079A BR9600079A BR9600079A BR9600079A BR 9600079 A BR9600079 A BR 9600079A BR 9600079 A BR9600079 A BR 9600079A BR 9600079 A BR9600079 A BR 9600079A BR 9600079 A BR9600079 A BR 9600079A
- Authority
- BR
- Brazil
- Prior art keywords
- osteosporosis
- saline
- treat
- compound
- pharmaceutical composition
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 201000009273 Endometriosis Diseases 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000017497 prostate disease Diseases 0.000 title 1
- 239000011780 sodium chloride Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/369,954 US5552412A (en) | 1995-01-09 | 1995-01-09 | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9600079A true BR9600079A (pt) | 1998-01-27 |
Family
ID=23457628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9600079A BR9600079A (pt) | 1995-01-09 | 1996-01-09 | Composto e intermediário para sua preparação composicão farmacêutica método para tratar ou prevenir osteosporose doenças cardiovasculares doença prostática obesidade câncer de mama endometriose e para baixar os niveis de colesterol no soro saguíneo |
Country Status (46)
Families Citing this family (183)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6974796B1 (en) | 1999-08-17 | 2005-12-13 | Girsh Leonard S | Therapeutic compositions for treatment of a damaged tissue |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
| IL120265A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists |
| IL120266A (en) * | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| CA2206752A1 (en) * | 1996-07-02 | 1998-01-02 | George Joseph Cullinan | Benzothiophene compounds, intermediates, processes, and methods of use |
| ID19392A (id) * | 1996-08-29 | 1998-07-09 | Lilly Co Eli | Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan |
| CA2215856A1 (en) * | 1996-09-26 | 1998-03-26 | Eli Lilly And Company | Dihydrobenzofluorene compounds, intermediates, compositions, and methods |
| CA2215647A1 (en) * | 1996-10-24 | 1998-04-24 | Eli Lilly And Company | Naphthyl compounds, compositions, and methods |
| US6034102A (en) * | 1996-11-15 | 2000-03-07 | Pfizer Inc | Atherosclerosis treatment |
| WO1998048806A1 (en) * | 1997-04-25 | 1998-11-05 | Eli Lilly And Company | Indene compounds having activity as serms |
| CA2231013A1 (en) * | 1997-04-30 | 1998-10-30 | Eli Lilly And Company | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals |
| CA2236254A1 (en) * | 1997-04-30 | 1998-10-30 | David Warren Hoard | Process for preparing benzo¬b|thiophenes |
| JP2001522372A (ja) * | 1997-04-30 | 2001-11-13 | イーライ・リリー・アンド・カンパニー | ベンゾチオフェンの製造方法 |
| CA2287922A1 (en) * | 1997-04-30 | 1998-11-05 | Eli Lilly And Company | Intermediates and processes for preparing benzo[b]thiophenes |
| WO1998048787A1 (en) * | 1997-04-30 | 1998-11-05 | Eli Lilly And Company | INTERMEDIATES AND A PROCESS FOR PREPARING BENZO[b]THIOPHENES |
| AU7165398A (en) * | 1997-04-30 | 1998-11-24 | Eli Lilly And Company | A regioselective alkylation process for preparing substituted benzo{b}thiophenes |
| AU8683398A (en) | 1997-08-07 | 1999-03-01 | Eli Lilly And Company | 1-{4-(substituted alkoxy)benzyl}naphthalene compounds having estrogen inhibitoryactivity |
| US6107346A (en) * | 1997-08-11 | 2000-08-22 | Eli Lilly And Company | Methods for treating hyperlipidemia |
| US5908859A (en) * | 1997-08-11 | 1999-06-01 | Eli Lilly And Company | Benzothiophenes for inhibiting hyperlipidemia |
| US20020037885A1 (en) * | 1999-07-22 | 2002-03-28 | Dijcks Fredericus Antonius | Therapeutic compounds |
| US6080773A (en) * | 1997-10-14 | 2000-06-27 | Akzo Nobel, N.V. | Benzylamine derivatives which are useful in treating psychiatric disorders |
| AU3352899A (en) * | 1997-12-11 | 1999-07-12 | American Home Products Corporation | 2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof |
| US6384057B1 (en) | 1997-12-11 | 2002-05-07 | American Home Products Corporation | 2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis |
| FR2778404B1 (fr) * | 1998-05-06 | 2000-06-30 | Hoechst Marion Roussel Inc | Derives du dihydro ou tetrahydronaphtalene, et les compositions pharmaceutiques les renfermant |
| ATE265853T1 (de) | 1998-06-16 | 2004-05-15 | Pfizer Prod Inc | Kombinationstherapeutika, enthaltend einen selektiven östrogenrezeptormodulator und prostaglandin e2 |
| PA8471201A1 (es) * | 1998-06-16 | 2000-09-29 | Pfizer Prod Inc | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea |
| DE19833786A1 (de) | 1998-07-18 | 2000-01-20 | Schering Ag | Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
| ID23459A (id) * | 1998-08-28 | 2000-04-27 | Pfizer Prod Inc | Biotransformasi mikroba |
| US6503917B1 (en) | 1998-12-10 | 2003-01-07 | Wyeth, Five Giralda Farms | 2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof |
| US6291456B1 (en) | 1998-12-30 | 2001-09-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6331562B1 (en) | 1998-12-30 | 2001-12-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6593322B1 (en) * | 1999-03-17 | 2003-07-15 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6436923B1 (en) | 1999-03-17 | 2002-08-20 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
| US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
| US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| YU26700A (sh) * | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
| HU230543B1 (hu) * | 1999-07-06 | 2016-11-28 | Endorecherche, Inc. | Inzulinrezisztencia kezelésére és/vagy megakadályozására szolgáló gyógyszerkészítmények |
| EP1086692A3 (en) * | 1999-07-28 | 2003-07-09 | Pfizer Products Inc. | Estrogen agonists and antagonists for multiple indications |
| US20070037777A1 (en) * | 2005-08-12 | 2007-02-15 | Immunopath Profile, Inc. | Lipid-containing compositions and methods of using them |
| US7790678B1 (en) * | 1999-08-17 | 2010-09-07 | Immunopath Profile, Inc. | Composition with anti-inflammatory, protein synthesizing, enzyme deficiency activating genetic therapy and anti-cancer activity and methods of use |
| US6436977B1 (en) * | 1999-09-29 | 2002-08-20 | Pfizer Inc. | Dosing regimens for lasofoxifene |
| AU1330901A (en) | 1999-10-06 | 2001-05-10 | Brigham And Women's Hospital | Compounds and methods for modulating non-transcriptional effects of steroid hormones |
| EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| CO5271709A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
| CO5271696A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
| CO5251465A1 (es) * | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
| AP2002002641A0 (en) | 2000-04-07 | 2002-12-31 | Pfizer Prod Inc | Estrogen agonist metabolites. |
| US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| DE60124616T2 (de) * | 2000-05-08 | 2007-09-13 | Pfizer Products Inc., Groton | Enzymatische Spaltung von selektiven Modulatoren des Östrogenrezeptors |
| NZ516582A (en) * | 2000-06-01 | 2004-08-27 | Watson Pharmaceuticals Inc | Transdermal delivery of lasofoxifene |
| AR029538A1 (es) | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
| EP1192945A3 (en) * | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
| JP2002117407A (ja) * | 2000-10-10 | 2002-04-19 | Satake Corp | 動画像検索方法及びその装置 |
| IL145838A (en) * | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis |
| TWI303990B (en) | 2000-10-17 | 2008-12-11 | Pfizer Prod Inc | New use of estrogen agonists/antagonists for improving vascular health |
| ATE288303T1 (de) * | 2000-11-30 | 2005-02-15 | Pfizer Prod Inc | Östrogen agonist-antagonist und testosteron enthaltende zusammensetzung zur behandlung abnehmender testosteronspiegel |
| AU2002222853A1 (en) * | 2000-12-07 | 2002-06-18 | Astrazeneca Ab | Therapeutic compounds |
| AU2002235348A1 (en) * | 2001-01-17 | 2002-07-30 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
| AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| US6599921B2 (en) | 2001-02-22 | 2003-07-29 | Nanodesign, Inc. | Non-steroidal estrogen receptor ligands |
| AU2756602A (en) * | 2001-04-25 | 2002-10-31 | Pfizer Products Inc. | Methods and kits for treating depression or preventing deterioration of cognitive function |
| US20020182646A1 (en) * | 2001-04-30 | 2002-12-05 | Ke Huazhu | Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders |
| AP2003002900A0 (en) * | 2001-05-01 | 2003-12-31 | Pfizer Prod Inc | Method for manufacturing a low dose pharmaceutical composition |
| US7425565B2 (en) * | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
| TWI224101B (en) | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| WO2003000253A1 (en) | 2001-06-20 | 2003-01-03 | Wyeth | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| EP1312363A1 (en) * | 2001-09-28 | 2003-05-21 | Pfizer Products Inc. | Methods of treatment and kits comprising a growth hormone secretagogue |
| US6884806B2 (en) | 2001-10-17 | 2005-04-26 | Bristol-Myers Squibb Company | Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US20040213841A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S | Methods for treating hot flashes and gynecomastia |
| US20040096510A1 (en) * | 2001-11-29 | 2004-05-20 | Steiner Mitchell S. | Prevention and treatment of androgen-deprivation induced osteoporosis |
| US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
| US7524866B2 (en) * | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
| US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
| ES2319785T3 (es) * | 2001-11-29 | 2009-05-12 | Gtx, Inc. | Prevencion y tratamiento de osteoporosis inducida por privacion de androgenos. |
| US20040214898A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
| US20050080143A1 (en) * | 2001-11-29 | 2005-04-14 | Steiner Mitchell S. | Treatment of androgen-deprivation induced osteoporosis |
| US7342884B2 (en) * | 2002-03-13 | 2008-03-11 | Harmonic, Inc. | Method and apparatus for one directional communications in bidirectional communications channel |
| ATE459599T1 (de) * | 2002-03-28 | 2010-03-15 | Pfizer Prod Inc | Gereinigtes lasofoxifen und verfahren zur aufreinigung von racemischem lasofoxifen durch umkristallisieren |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| US6608212B1 (en) * | 2002-06-04 | 2003-08-19 | Pfizer, Inc. | Process for preparing vinylaromatic compounds |
| PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
| HRP20041233A2 (en) | 2002-07-22 | 2005-02-28 | Eli Lilly And Company | Selective estrogen receptor modulators containing a phenylsulfonyl group |
| US9315539B2 (en) * | 2002-10-01 | 2016-04-19 | Yale University | 11 beta-short chain substituted estradiol analogs and their use in the treatment of menopausal symptoms and estrogen sensitive cancer |
| JP2006514637A (ja) | 2002-12-10 | 2006-05-11 | ワイス | プラスミノーゲン活性化因子の阻害因子−１（ｐａｉ−１）の阻害剤としての置換３−カルボニル−１ｈ−インドール−１−イル酢酸誘導体 |
| JP2006510673A (ja) | 2002-12-10 | 2006-03-30 | ワイス | プラスミノゲンアクティベータインヒビター１（ｐａｉ−１）のインヒビターとしての、アリール、アリールオキシ、および、アルキルオキシ置換１ｈ−インドール−３−イルグリオキシル酸誘導体 |
| US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
| CA2509222A1 (en) | 2002-12-10 | 2004-06-24 | Wyeth | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| ES2268480T3 (es) | 2002-12-10 | 2007-03-16 | Wyeth | Derivados del acido 3-alquilo- y 3-arilalquilo-1h-indol-1-il-acetico sustituidos como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1). |
| UA80453C2 (en) | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
| AU2003292625B2 (en) | 2002-12-26 | 2008-07-24 | Eisai R & D Management Co., Ltd. | Selective estrogen receptor modulators |
| US7332525B2 (en) | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
| JP2006516276A (ja) * | 2003-01-22 | 2006-06-29 | ファイザー・プロダクツ・インク | エストロゲンアゴニスト／アンタゴニストを使用して、関節痛を治療または睡眠を改善する方法 |
| CA2523830A1 (en) * | 2003-04-30 | 2004-11-11 | Debiopharm S.A. | Methods and compositions using gonadotropin hormone releasing hormone |
| US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
| MXPA06003122A (es) * | 2003-09-19 | 2006-05-31 | Pfizer Prod Inc | Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos. |
| US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
| US7351726B2 (en) | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
| US7163954B2 (en) | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
| US7420083B2 (en) | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
| US7442805B2 (en) | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
| US7342039B2 (en) | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
| US7265148B2 (en) | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
| US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
| US7268159B2 (en) | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
| US7582773B2 (en) | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
| US7446201B2 (en) | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
| US7332521B2 (en) | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
| US7141592B2 (en) | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
| MXPA06006810A (es) * | 2003-12-17 | 2006-08-23 | Pfizer Prod Inc | Tratamiento de afecciones que se presentan con un nivel bajo de masa osea por terapia de combinacion continua con agonistas selectivos del receptor de prostaglandina ep4 y un estrogeno. |
| EP1709022A1 (en) * | 2004-01-22 | 2006-10-11 | Eli Lilly And Company | Selective estrogen receptor modulators |
| WO2005073190A1 (en) * | 2004-01-29 | 2005-08-11 | Eli Lilly And Company | Selective estrogen receptor modulators |
| US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
| US20050203086A1 (en) * | 2004-03-04 | 2005-09-15 | Pfizer Inc. | Methods of treatment using an EP2 selective receptor agonist |
| EP1732888A1 (en) | 2004-04-08 | 2006-12-20 | Wyeth | Bazedoxifene ascorbate as selective estrogen receptor modulator |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| US7799273B2 (en) | 2004-05-06 | 2010-09-21 | Smp Logic Systems Llc | Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes |
| US7444197B2 (en) * | 2004-05-06 | 2008-10-28 | Smp Logic Systems Llc | Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes |
| MXPA06015170A (es) * | 2004-06-21 | 2007-08-21 | Pharmacia & Upjohn Co Llc | Procedimiento para aumentar la cantidad de hueso. |
| JP2008509999A (ja) * | 2004-08-17 | 2008-04-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 選択的なエストロゲン受容体モジュレーターとしてのベンズオキサゼピン誘導体 |
| WO2006023866A2 (en) | 2004-08-23 | 2006-03-02 | Wyeth | Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1 |
| RU2007106868A (ru) | 2004-08-23 | 2008-09-27 | Вайет (Us) | Оксазол-нафтиловые кислоты и их применение в качестве модуляторов ингибитора активатора плазминогена-1 (pai) для лечения тромбоза и сердечно-сосудистых заболеваний |
| JP2008510814A (ja) | 2004-08-23 | 2008-04-10 | ワイス | Ｐａｉ−１阻害剤としてのピロロ−ナフチル酸 |
| AU2005308575A1 (en) * | 2004-11-23 | 2006-06-01 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia |
| JP2008528618A (ja) | 2005-01-27 | 2008-07-31 | ワイス | 置換ナフチルインドール誘導体の調製のための方法および化合物 |
| EP1937251A2 (en) * | 2005-04-25 | 2008-07-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
| JP2009501143A (ja) * | 2005-06-22 | 2009-01-15 | ファイザー・プロダクツ・インク | シス−６−フェニル−５−［４−（２−ピロリジン−１−イル−エトキシ）−フェニル］−２−メトキシ−５，６，７，８−テトラヒドロナフタレン塩酸塩を調製するための立体選択的水素化方法 |
| PL1912650T3 (pl) * | 2005-08-03 | 2018-01-31 | Sprout Pharmaceuticals Inc | Zastosowanie flibanseryny w leczeniu otyłości |
| US7683091B2 (en) | 2005-08-17 | 2010-03-23 | Wyeth | Substituted indoles and methods of their use |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| EP1945214A1 (en) | 2005-10-29 | 2008-07-23 | Boehringer Ingelheim International GmbH | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| JP5212931B2 (ja) | 2006-01-26 | 2013-06-19 | 学校法人東京理科大学 | ラソフォキシフェン及びその類縁体の製造方法 |
| WO2007128802A2 (en) * | 2006-05-09 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of post-menopausal sexual desire disorders |
| DE602007004615D1 (de) | 2006-06-30 | 2010-03-18 | Boehringer Ingelheim Pharma | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen |
| US20090318469A1 (en) * | 2006-07-14 | 2009-12-24 | Boehringer Ingelheim International Gmbh | Use of Flibanserin for the Treatment of Sexual Disorders in Females |
| MX2009001551A (es) | 2006-08-14 | 2009-02-20 | Boehringer Ingelheim Int | Formulaciones de flibanserina y metodo para fabricarlas. |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| MX2009002031A (es) * | 2006-08-25 | 2009-03-06 | Boehringer Ingelheim Int | Sistema de liberacion controlada y metodo para fabricarlo. |
| ES2382009T3 (es) | 2006-12-01 | 2012-06-04 | Bristol-Myers Squibb Company | Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares |
| WO2008090742A1 (ja) * | 2007-01-23 | 2008-07-31 | National University Corporation Hokkaido University | 眼疾患モデル用非ヒト動物 |
| CZ2007373A3 (cs) * | 2007-05-29 | 2008-12-10 | Zentiva, A. S | Zpusob prípravy lasofoxifenu |
| US20090062374A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched lasofoxifene |
| CL2008002693A1 (es) * | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
| KR101493472B1 (ko) | 2007-10-16 | 2015-02-16 | 레프로스 쎄라피우틱스 아이엔씨. | 대사증후군 치료를 위한 트랜스―클로미펜 |
| US8003689B2 (en) * | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| WO2010125578A2 (en) * | 2009-04-29 | 2010-11-04 | Glenmark Generics Limited | A process for the preparation of lasofoxifene tartrate |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| CN102311406A (zh) * | 2010-06-29 | 2012-01-11 | 武汉启瑞药业有限公司 | 拉索昔芬中间体的制备方法 |
| CN102464629A (zh) * | 2010-11-12 | 2012-05-23 | 上海医药工业研究院 | 1-{2-[4-(6-甲氧基-2-苯基-3,4-二氢萘-1-基)苯氧基]乙基}吡咯烷的制备方法 |
| EP2524908A1 (en) | 2011-05-20 | 2012-11-21 | LEK Pharmaceuticals d.d. | Process for the preparation of alfa-substituted ketones and their application in synthesis of pharmaceutically active compounds |
| DE102011087987A1 (de) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| CN102643178A (zh) * | 2012-02-08 | 2012-08-22 | 浙江华海药业股份有限公司 | 一种酒石酸拉索昔芬及其中间体的制备方法 |
| ES2681023T3 (es) | 2012-02-29 | 2018-09-11 | Repros Therapeutics Inc. | Terapia de combinación para tratar el déficit de andrógenos |
| CN103113323B (zh) * | 2013-02-05 | 2015-11-11 | 南京华威医药科技开发有限公司 | 酒石酸拉索昔芬中间体的制备方法 |
| WO2015092634A1 (en) * | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| ES2939940T3 (es) | 2014-03-28 | 2023-04-28 | Univ Duke | Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos |
| KR102664618B1 (ko) * | 2015-05-29 | 2024-05-10 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 사치환된 알켄 화합물 및 그의 용도 |
| JP6920295B2 (ja) * | 2015-11-09 | 2021-08-18 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用 |
| JP7048505B2 (ja) | 2015-11-10 | 2022-04-05 | パラクリン セラピューティクス エービー | Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 |
| EP3440067B1 (en) | 2016-04-08 | 2021-05-26 | F. Hoffmann-La Roche AG | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| CN112933082A (zh) | 2016-10-11 | 2021-06-11 | 杜克大学 | Er+乳腺癌的拉索昔芬治疗 |
| AU2017363699B2 (en) | 2016-11-28 | 2021-02-18 | Eisai R&D Management Co., Ltd. | Salts of indazole derivative and crystals thereof |
| WO2019164861A1 (en) | 2018-02-21 | 2019-08-29 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
| EP3773524B1 (en) | 2018-04-10 | 2025-04-09 | Duke University | Lasofoxifene for the treatment of er+ breast cancer carrying the mutation d538g or y537s |
| CN109317203B (zh) * | 2018-12-03 | 2019-09-03 | 毕云丽 | 一种治疗绝经后妇女骨质疏松症用药物中间体的制备方法 |
| WO2022178139A1 (en) * | 2021-02-19 | 2022-08-25 | The University Of Chicago | Estrogen receptor alpha antagonists and uses thereof |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| WO2025043004A1 (en) | 2023-08-21 | 2025-02-27 | Duke University | Treatment of solid cancer with lasofoxifene |
| TW202528295A (zh) * | 2023-12-11 | 2025-07-16 | 美商富士軟片電子材料美國股份有限公司 | 茚烷雙－鄰－胺基酚及由其製備之聚合物 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3396169A (en) * | 1966-10-26 | 1968-08-06 | Upjohn Co | Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes |
| US3274213A (en) * | 1961-09-05 | 1966-09-20 | Upjohn Co | Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes |
| US3234090A (en) * | 1962-09-10 | 1966-02-08 | Ciba Geigy Corp | Pharmaceutical compositions comprising saturated basic ethers |
| US3227730A (en) * | 1963-05-01 | 1966-01-04 | Union Carbide Corp | Stabilization of lactones |
| US3862232A (en) * | 1963-07-03 | 1975-01-21 | Upjohn Co | 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof |
| US3293263A (en) * | 1963-12-09 | 1966-12-20 | Upjohn Co | Diphenylbenzocycloalkenes |
| US3522319A (en) * | 1964-01-23 | 1970-07-28 | Ciba Geigy Corp | Phenol substituted tetrahydronaphthalenes useful as estrogenics |
| US3320271A (en) * | 1964-06-01 | 1967-05-16 | Upjohn Co | 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes |
| US3483293A (en) * | 1967-12-15 | 1969-12-09 | Upjohn Co | Method for controlling birds and rodents |
| US3567737A (en) * | 1968-01-02 | 1971-03-02 | Upjohn Co | Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes |
| US3875242A (en) | 1968-01-02 | 1975-04-01 | Upjohn Co | Compounds and process for preparing the same |
| DE2345422C2 (de) * | 1973-09-08 | 1983-12-22 | Dr. Karl Thomae Gmbh, 7950 Biberach | Substituierte Isochinolyl-arylpiperazine diese enthaltende Arzneimittel sowie Verfahren zu deren Herstellung |
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| CA1164459A (en) * | 1980-11-11 | 1984-03-27 | Yung-Hsiung Yang | Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US4358593A (en) * | 1981-04-03 | 1982-11-09 | Eli Lilly And Company | Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| PH19604A (en) * | 1982-06-04 | 1986-05-27 | Egyt Gyogyszervegyeszeti Gyar | Isoquinoline derivatives and pharmaceutical compositions containing the same |
| DE3233424A1 (de) * | 1982-09-09 | 1984-03-15 | Hoechst Ag, 6230 Frankfurt | Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| DE3918544A1 (de) * | 1989-06-07 | 1990-12-13 | Bayer Ag | Verfahren zur herstellung von 7-(3-amino- sowie 3-amino-methyl-1-pyrrolidinyl)-3-chinolon- carbonsaeuren sowie -naphthyridoncarbonsaeuren |
| US5084461A (en) * | 1991-03-27 | 1992-01-28 | Merrell Dow Pharmaceuticals Inc. | Azadecalin amides and thioamides as inhibitors of cholesterol biosynthesis |
| DE4117512A1 (de) * | 1991-05-25 | 1992-11-26 | Schering Ag | 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
| TW241258B (enExample) * | 1992-04-15 | 1995-02-21 | Takeda Pharm Industry Co Ltd | |
| EP0586229A1 (en) * | 1992-09-01 | 1994-03-09 | Zeneca Limited | 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors |
| TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
| US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
| US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| US5492921A (en) * | 1994-09-20 | 1996-02-20 | Eli Lilly And Company | Benzothiophene compounds, compositions, and methods for inhibiting aortal smooth muscle proliferation |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
| US5532382A (en) * | 1995-03-13 | 1996-07-02 | Eli Lilly And Company | Benzothiophenes substituted at the 3-carbonyl |
| US5567828A (en) * | 1995-06-07 | 1996-10-22 | Eli Lilly And Company | Compounds and compositions with nitrogen-containing non-basic side |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| UA59384C2 (uk) * | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| US6124314A (en) * | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
| AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| EP1411922A1 (en) * | 2001-07-31 | 2004-04-28 | Pfizer Products Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
| DE102012218742A1 (de) | 2012-10-15 | 2014-04-17 | Deere & Company | Nachdrescheinrichtung für einen Mähdrescher |
-
1995
- 1995-01-09 US US08/369,954 patent/US5552412A/en not_active Ceased
- 1995-04-24 EP EP20030026477 patent/EP1411049A1/en not_active Withdrawn
- 1995-04-24 CA CA002209925A patent/CA2209925C/en not_active Expired - Lifetime
- 1995-04-24 EP EP01120246A patent/EP1151998A1/en not_active Withdrawn
- 1995-04-24 EP EP95914493A patent/EP0802910B1/en not_active Expired - Lifetime
- 1995-04-24 ES ES95914493T patent/ES2172579T3/es not_active Expired - Lifetime
- 1995-04-24 WO PCT/IB1995/000286 patent/WO1996021656A1/en not_active Ceased
- 1995-04-24 DE DE69525857T patent/DE69525857T2/de not_active Expired - Lifetime
- 1995-04-24 PT PT95914493T patent/PT802910E/pt unknown
- 1995-04-24 DE DE122009000047C patent/DE122009000047I1/de active Pending
- 1995-04-24 US US08/849,726 patent/US6204286B1/en not_active Expired - Lifetime
- 1995-04-24 DK DK95914493T patent/DK0802910T3/da active
- 1995-04-24 JP JP8521528A patent/JP2972347B2/ja not_active Expired - Lifetime
- 1995-04-24 AT AT95914493T patent/ATE214382T1/de active
- 1995-12-14 AP APAP/P/1995/000774A patent/AP592A/en active
- 1995-12-22 SK SK1648-95A patent/SK281992B6/sk not_active IP Right Cessation
- 1995-12-22 CO CO95061202A patent/CO4600740A1/es unknown
- 1995-12-28 UA UA95125539A patent/UA46710C2/uk unknown
- 1995-12-30 TW TW084114170A patent/TW313567B/zh not_active IP Right Cessation
-
1996
- 1996-01-01 IL IL11664396A patent/IL116643A/xx not_active IP Right Cessation
- 1996-01-01 IL IL13076196A patent/IL130761A/xx not_active IP Right Cessation
- 1996-01-03 PE PE1996000003A patent/PE46597A1/es not_active Application Discontinuation
- 1996-01-03 SG SG1996000020A patent/SG47377A1/en unknown
- 1996-01-03 MY MYPI96000009A patent/MY115784A/en unknown
- 1996-01-03 MA MA24123A patent/MA23768A1/fr unknown
- 1996-01-04 AR ARP960100879A patent/AR003917A1/es unknown
- 1996-01-05 RU RU96100074A patent/RU2130454C1/ru active
- 1996-01-05 IS IS4316A patent/IS1916B/is unknown
- 1996-01-08 RO RO96-00021A patent/RO116275B1/ro unknown
- 1996-01-08 PL PL96312182A patent/PL183474B1/pl unknown
- 1996-01-08 LV LVP-96-04A patent/LV11460B/en unknown
- 1996-01-08 ZA ZA9695A patent/ZA9695B/xx unknown
- 1996-01-08 CN CN96100634A patent/CN1059902C/zh not_active Expired - Lifetime
- 1996-01-08 KR KR1019960000199A patent/KR100190727B1/ko not_active Expired - Lifetime
- 1996-01-08 RS YU596A patent/RS49531B/sr unknown
- 1996-01-08 NO NO960081A patent/NO305435B1/no not_active IP Right Cessation
- 1996-01-08 NZ NZ280792A patent/NZ280792A/en not_active IP Right Cessation
- 1996-01-08 CZ CZ9655A patent/CZ285085B6/cs not_active IP Right Cessation
- 1996-01-09 BG BG100278A patent/BG62256B1/bg unknown
- 1996-01-09 HU HU9600056A patent/HU224077B1/hu active Protection Beyond IP Right Term
- 1996-01-09 AU AU40916/96A patent/AU700982B2/en not_active Expired
- 1996-01-09 BR BR9600079A patent/BR9600079A/pt not_active IP Right Cessation
- 1996-01-09 SI SI9600004A patent/SI9600004A/sl not_active IP Right Cessation
- 1996-01-09 OA OA60765A patent/OA10254A/en unknown
- 1996-01-09 TR TR96/00001A patent/TR199600001A2/xx unknown
- 1996-01-09 HR HR960010A patent/HRP960010B1/xx not_active IP Right Cessation
- 1996-01-09 EG EG1896A patent/EG23913A/xx active
- 1996-02-07 SA SA96160584A patent/SA96160584B1/ar unknown
-
1997
- 1997-07-08 FI FI972903A patent/FI116525B/fi not_active IP Right Cessation
-
1998
- 1998-08-28 US US09/141,613 patent/US6153622A/en not_active Expired - Lifetime
-
1999
- 1999-07-01 IL IL13076199A patent/IL130761A0/xx unknown
- 1999-12-17 US US09/466,034 patent/US6441193B1/en not_active Expired - Lifetime
-
2000
- 2000-10-24 IL IL13923500A patent/IL139235A0/xx unknown
-
2001
- 2001-03-28 US US09/820,158 patent/US20010025051A1/en not_active Abandoned
-
2002
- 2002-05-16 US US10/147,725 patent/US20020132816A1/en not_active Abandoned
-
2004
- 2004-12-23 US US11/022,427 patent/USRE39558E1/en not_active Expired - Lifetime
-
2009
- 2009-08-19 LU LU91599C patent/LU91599I2/fr unknown
- 2009-08-21 NO NO2009018C patent/NO2009018I2/no unknown
- 2009-08-24 NL NL300405C patent/NL300405I2/nl unknown
-
2010
- 2010-08-20 US US12/860,099 patent/US20100317712A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9600079A (pt) | Composto e intermediário para sua preparação composicão farmacêutica método para tratar ou prevenir osteosporose doenças cardiovasculares doença prostática obesidade câncer de mama endometriose e para baixar os niveis de colesterol no soro saguíneo | |
| EE200100507A (et) | Hüdroksümatairesinool vähkkasvaja vältimises | |
| EP0841932A4 (en) | IMPROVED DRUG ADMINISTRATION THROUGH MODIFIED SAPONINE | |
| BRPI0410129A (pt) | uso terapêutico de anticorpos anti-cs1 | |
| AU1807401A (en) | Compositions and methods for therapy and diagnosis of breast cancer | |
| IL214084A (en) | Kit containing antibodies against antibb2 and instructions for use in breast cancer treatment | |
| EP1515982A4 (en) | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER | |
| WO2001008636A8 (en) | Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein | |
| BR9814435A (pt) | Novos esteróides antiestrogênicos e composições farmacêuticas associadas | |
| PL365244A1 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
| AU6098600A (en) | Determining antibodies to ny-eso-1 in cancer patients | |
| IL132287A0 (en) | Compositions and methods for the treatment and diagnosis of breast cancer | |
| AU3391200A (en) | Compositions and methods for breast cancer therapy and diagnosis | |
| BR9607967A (pt) | Uso de composições imunomodulares extraídas da bile para o tratamento das desordens do sistema imunológico fabricação do medicamento e emprego do mesmo | |
| FR2756490B1 (fr) | Methodes de prevention du cancer du sein | |
| EE200000333A (et) | Eesnäärmevähi ravis kasutatav konjugaat ning farmatseutiline kompositsioon ja selle valmistamismeetod | |
| ATE325803T1 (de) | Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung | |
| WO2002087503A3 (en) | Compositions and methods for treating colorectal polyps and cancer | |
| IL121217A0 (en) | Pharmaceutical composition for treating chronic progressive vascular diseases | |
| WO2000030425A3 (en) | Method of using pon-1 to decrease atheroma formation | |
| HUP0402023A3 (en) | Use of anastrozole in the preparation of pharmaceutical compositions for the treatment of post-menopausal women having early breast cancer | |
| AU5638400A (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
| BR0114655A (pt) | Método para a identificação de uma combinação de drogas para tratamento de câncer de mama em um animal, método para o tratamento de câncer de mama em um animal, método para a identificação de uma combinação de drogas para a prevenção de câncer de mama em um animal predisposto ao referido câncer, método de prevenção de câncer de mama em um animal predisposto ao referido câncer, método para a otimização de tratamento de um paciente com câncer de mama, método para a otimização de um regime de prevenção de câncer em um animal, conjunto útil para o tratamento de câncer de mama em um paciente em necessidade de tratamento e composição farmacêutica para tratamento ou prevenção de câncer de mama | |
| HUP9900309A3 (en) | Use of ridogrel for producing pharmaceutical compositions for the treatment of inflammatory bowel diseases | |
| FR2759906B1 (fr) | Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
| FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 09/01/2016 |